Less than a month after reports of takeover talks between AbbVie and Gilgamesh Pharma first emerged, the pair have gone public with details of a $1.2 billion deal – but it is not an acquisition. It ...
AbbVie has agreed to pay $65 million on an option deal with start-up Gilgamesh Pharma, lining up rights to neuroplastogen compounds that can improve neuroplasticity - the ability of the brain to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback